Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | CKS1B | P61024 | 2/20 | 0.47 |
| ▸ | SKP1 | P63208 | 2/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17207585 | 0.88 | CYP11B2 (0.59) | CYP11B2GPR119CKS1BSKP1SKP2 | |
| SCHEMBL17207592 | 0.83 | CYP11B2 (0.59) | CYP11B2GPR119CKS1BSKP1SKP2 | |
| SCHEMBL18502914 | 0.80 | SCD5 (0.45) | CYP11B2GPR119CKS1BSKP1SKP2 | |
| SCHEMBL17207602 | 0.79 | GPR119 (0.47) | GPR119CKS1BSKP1SKP2SMN1; SMN2 | |
| SCHEMBL18502952 | 0.78 | CYP11B2 (0.52) | CYP11B2GPR119CKS1BSKP1SKP2 | |
| SCHEMBL17207553 | 0.78 | CYP11B2 (0.75) | CYP11B2 | |
| SCHEMBL18502895 | 0.76 | CYP11B2 (0.68) | CYP11B2 | |
| SCHEMBL17207658 | 0.76 | GPR119 (0.43) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL25458611 | 0.75 | CKS1B (0.48) | GPR119CKS1BSKP1SKP2SMN1; SMN2 | |
| SCHEMBL18502870 | 0.75 | CYP11B2 (0.51) | CYP11B2GPR119CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | NR3C2, REN, CYP21A2 | CYP11B2 17/4885GPR119 611/4885CKS1B 180/4885 |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | CYP11B2 19/4885GPR119 664/4885CKS1B 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.